Abstract
Relative to placebo, selective serotonin reuptake inhibitors (SSRI) are efficacious for paediatric affective disorders, although their clinical effects appear relatively modest in major depressive disorder, intermediate in obsessive-compulsive disorder, and stronger in anxiety disorders. If SSRIs modestly increase the risk of occurrence of suicidal ideation and behavior, several studies show that their use is associated with a significant decrease in the suicide rates in children and adolescents, probably because of their efficacy, compliance, and low toxicity in overdose.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call